CA9 and neoplasm: Based on dosimetry, the liver was expected to be the dose-limiting organ for therapeutic studies, therefore a maximum injected activity of 24 MBq [177Lu]Lu-DOTA-hG250, resulting in a dose of 106±67 Gy to the liver for Renca-CAIX tumor-bearing mice, was used.